about
Proteomic analysis of human very low-density lipoprotein by two-dimensional gel electrophoresis and MALDI-TOF/TOFEvidence for a common progenitor of epithelial and mesenchymal components of the liver.Determination of anti-HIV drug concentration in human plasma by MALDI-TOF/TOF.Proteomic analysis of anti-angiogenic effects by a combined treatment with vinblastine and rapamycin in an endothelial cell line.The RNA-dependent RNA polymerase essential for post-transcriptional gene silencing in Neurospora crassa interacts with replication protein A.Determination of abacavir, amprenavir, didanosine, efavirenz, nevirapine, and stavudine concentration in human plasma by MALDI-TOF/TOF.Analysis of the periplasmic proteome of Pseudomonas aeruginosa, a metabolically versatile opportunistic pathogen.Proteomic profiling of PrP27-30-enriched preparations extracted from the brain of hamsters with experimental scrapie.Mitochondrial localization of PARP-1 requires interaction with mitofilin and is involved in the maintenance of mitochondrial DNA integrityDetermination of antituberculosis drug concentration in human plasma by MALDI-TOF/TOF.SILAC labeling coupled to shotgun proteomics analysis of membrane proteins of liver stem/hepatocyte allows to candidate the inhibition of TGF-beta pathway as causal to differentiation.Discovery of chemotherapy-associated ovarian cancer antigens by interrogating memory T cells.EIF6 over-expression increases the motility and invasiveness of cancer cells by modulating the expression of a critical subset of membrane-bound proteinsCD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 lncRNA.Extracellular Matrix Molecular Remodeling in Human Liver Fibrosis Evolution.Function and ribosomal localization of aIF6, a translational regulator shared by archaea and eukarya.Elucidation of lipoprotein particles structure by proteomic analysis.Applying proteomic technology to clinical virology.Molecular mechanisms controlling the phenotype and the EMT/MET dynamics of hepatocyte.Spike-in SILAC proteomic approach reveals the vitronectin as an early molecular signature of liver fibrosis in hepatitis C infections with hepatic iron overload.TGFβ overrides HNF4α tumor suppressing activity through GSK3β inactivation: implication for hepatocellular carcinoma gene therapy.Ferritin heavy chain is the host factor responsible for HCV-induced inhibition of apoB-100 production and is required for efficient viral infection.The stable repression of mesenchymal program is required for hepatocyte identity: a novel role for hepatocyte nuclear factor 4α.Proteomic analysis reveals a major role for contact inhibition in the terminal differentiation of hepatocytes.ERK5/MAPK is activated by TGFbeta in hepatocytes and required for the GSK-3beta-mediated Snail protein stabilization.Overexpression of the Vitronectin V10 Subunit in Patients with Nonalcoholic Steatohepatitis: Implications for Noninvasive Diagnosis of NASH.The occurrence of the psbS gene product in Chlamydomonas reinhardtii and in other photosynthetic organisms and its correlation with energy quenching.Very low density lipoprotein and low density lipoprotein isolated from patients with hepatitis C infection induce altered cellular lipid metabolismMatrisome analysis of intrahepatic cholangiocarcinoma unveils a peculiar cancer-associated extracellular matrix structureGenetic Basis and Physiological Effects of Lipid A Hydroxylation in Pseudomonas aeruginosa PAO1
P50
Q24323213-63E7055E-B614-4D19-B934-8EDE4F8EF78DQ30541269-0BAE5ACF-43A0-4C21-918C-30DC7669B712Q33235049-7BB551A1-CC12-4CE8-9D48-C980A7226E14Q33252847-0582A72E-45B6-4C09-9959-545FA5140C2CQ33307904-6EC7BD43-48D9-41E0-9DB5-729065E4A567Q33318736-4B9E56B1-0227-45AA-A7D5-FBAA6A69C9A3Q33424597-184D7C67-0969-4F9E-9A20-D4420F0E0093Q33487890-E0B4648E-FD4F-4DF9-8C15-8A786BA3CAB9Q33504492-15CD389F-C968-406D-9C2D-458746878DDFQ33543869-4E8E1705-F329-427D-883D-FF3685A4B0F6Q33558317-A3A1A614-84D6-4EBB-ABB1-FF7EF887EC1FQ35024484-B4EE443B-9A7D-45FF-8D20-A2AD9F9B1470Q35237787-1B4AF6BD-562C-48D4-84CC-8D072E08EDEAQ35954464-4A1C7FDA-8046-4B83-8714-BE8FCA9061AAQ35964516-67C5C3A1-B6F3-4950-AD40-A7781DCCDB0DQ37041845-31220AB4-E72F-477D-96D4-F4C21B8F8E27Q37087392-121B8DEC-811D-4D76-88DE-379DF17A780DQ38049192-51E3F49D-584C-42D3-B30C-33AA54124801Q38207092-7CB6607F-D0F9-458E-ADEC-54C211ECFF03Q39016620-CEE1BFD7-507B-45E0-B5F2-91F318E38F60Q39283004-7E6D08F5-8192-44AF-8C5B-CD1A6123320CQ39374849-C505BFAE-AA79-480B-B356-6EA92802F2E4Q39579573-7831C6CB-33A7-4A14-9C47-AD7D94EBCFEBQ39759737-1A8A7BEC-8528-4FCE-8ACB-E3CC811B8F0CQ39945102-3BD4955C-573C-46D7-944F-4F434D90092EQ49804078-2BD5E54A-6F4F-490B-9A2A-23AC3F21808AQ50609877-102ECE91-5360-4604-950B-769935198A50Q61890245-40BF9761-595C-4705-AD59-3082B4356D5DQ91112437-E29706F7-8FC6-4ACA-814D-5EC293D45663Q91963635-31887A15-CFE3-4147-B64A-3044C188DBAD
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Carmine Mancone
@ast
Carmine Mancone
@en
Carmine Mancone
@es
Carmine Mancone
@nl
Carmine Mancone
@sl
type
label
Carmine Mancone
@ast
Carmine Mancone
@en
Carmine Mancone
@es
Carmine Mancone
@nl
Carmine Mancone
@sl
prefLabel
Carmine Mancone
@ast
Carmine Mancone
@en
Carmine Mancone
@es
Carmine Mancone
@nl
Carmine Mancone
@sl
P106
P1153
23501862200
P31
P496
0000-0002-9569-5030